The pharmaceutical company Endo International on Thursday announced a $50 million settlement with the New York Attorney General’s Office and Suffolk and Nassau counties, removing another defendant from New York’s sprawling opioid trial, which began in June on Long Island.
Endo and its subsidiaries, including Endo Pharmaceuticals and Par Pharmaceuticals, has agreed to pay $22.3 million to the attorney general’s office and $13.85 million to each of the counties to resolve the suit, in which the government officials alleged that the companies were in part responsible for the opioid crisis.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
